SEQH CAPITAL RESEARCH - TEAR SHEET
NUCLEAR’S HIDDEN BALANCE SHEET - THE FEDERAL BACKSTOP IS MOSTLY FUTURE OPTION VALUE, NOT CURRENT FINANCING
WHAT THIS REPORT ARGUES
Nuclear and fuel-cycle equities are often valued as if federal policy has already lowered their cost of capital through DOE loans, Price-Anderson liability protection, and IRA tax credits.
SEQH’s central finding is that, across Energy Fuels, Oklo, NuScale, NANO Nuclear, and ASP Isotopes, most of that support remains prospective rather than realized. None holds a DOE Title 17 or Energy Dominance Financing loan today, and only Oklo has any live component of the three-pillar policy framework.
The three pillars
The report evaluates three mechanisms commonly embedded in nuclear-equity narratives: DOE Title 17 or Energy Dominance Financing, Price-Anderson Act liability protection, and IRA Sections 45U and 48E.
Title 17 and Energy Dominance Financing can lower funding costs through long-term federally backed financing, but recent nuclear deals have gone to established utilities, reactor restarts, or large supply-chain projects rather than to pre-revenue reactor or fuel-cycle developers.
Price-Anderson is a liability and bankability framework, not simply a lower-interest-rate benefit. It matters because the private market cannot readily insure catastrophic nuclear liability at scale.
Sections 45U and 48E can potentially improve project economics through production or investment tax credits, but they are not broadly available to the five companies in this report today.
Title 17 reality check
None of the five covered names holds a Title 17 loan, federal guarantee, or conditional commitment as of the report date.
The recent federal financing winners include Palisades at $1.52 billion, Constellation’s Crane restart at $1 billion, Southern Company at $26.5 billion, Duane Arnold at $1.9 billion, and a conditional $17.5 billionAP1000 supply-chain package.
These transactions share a common profile: existing assets, investment-grade utilities, or industrial-scale buildouts with clearer cash-flow visibility than early-stage developers.
The report’s conclusion is that the market is not pricing a current basis-point funding advantage for the five names. It is pricing the possibility that one or more eventually becomes bankable enough to access a facility that does not yet exist.
Price-Anderson is narrower
Only Oklo has a current Price-Anderson component, and even that is not full commercial-reactor coverage. It is a DOE contractor indemnity associated with its Reactor Pilot Program activity at Idaho National Laboratory.
NuScale has a design approval, but its eventual Price-Anderson coverage would attach to a future plant owner or customer licensee, not to NuScale itself as the technology vendor.
NANO Nuclear has only a third-party pathway through the University of Illinois KRONOS construction permit application. The license belongs to the university, not to NNE.
Energy Fuels is outside the framework because its operations rely on materials licenses rather than an NRC reactor license.
ASP Isotopes is structurally excluded even in a hypothetical future enrichment-plant scenario, because post-1992 uranium enrichment facilities are excluded from Price-Anderson coverage under the relevant statute.
Tax-credit reality
Section 45U is unavailable to all five companies because it applies only to nuclear reactors placed in service before August 16, 2022.
Section 48E is more relevant to future nuclear builds, offering a 6 percent base investment credit that can rise to roughly 30 percent with labor compliance and potentially toward 50 percent with additional incentives.
But among the five names, only Oklo has made an explicit first-party argument that it could benefit as a future owner-operator. Even then, the report finds no disclosed monetization strategy, no realized credit proceeds, and no market-clearing reference transaction for a first-of-a-kind new nuclear project.
NuScale’s potential tax-credit benefit would accrue to a future customer or plant owner rather than to NuScale itself, while Energy Fuels, NANO Nuclear, and ASP Isotopes do not generate electricity and therefore do not qualify under the relevant power-generation credits.
Company implications
Energy Fuels has a real $725 million federal facility, but it comes from the Department of War’s Office of Strategic Capital rather than DOE Title 17. That creates a separate policy dependency tied to defense budgets, industrial policy, and critical-minerals strategy.
Oklo has the strongest partial factual basis for a federal-backstop narrative through pilot-phase DOE indemnity and its stated future 48E eligibility. However, the central risk is that neither benefit has become a commercial-scale, monetized asset.
NuScale is strongly associated with federal nuclear support in investor narratives, yet the report finds no current first-party Title 17 financing, Price-Anderson coverage, or tax-credit benefit. Its prior Title 17 application was tied to the terminated Carbon Free Power Project.
NANO Nuclear benefits from a real regulatory milestone at the University of Illinois, but the license and any associated liability framework belong to the university rather than to NNE directly.
ASP Isotopes sits outside all three mechanisms. Its enrichment and isotope ambitions are financed through industrial partnerships and private financing rather than current DOE loan support, Price-Anderson coverage, or relevant electricity tax credits.
The real valuation question
The report’s most important distinction is between existing legal support and future policy optionality.
Federal programs may still matter materially to these companies over time, especially as licensing, commercial deployment, customer commitments, and financing structures evolve.
But as of the report date, the supposed federal discount is mostly not a current balance-sheet benefit. It is a forward-looking expectation that policy pathways will mature, remain available, and ultimately convert into financeable projects.
That makes the sector sensitive not only to execution and licensing risk, but to legislative, regulatory, and financing-framework risk.
Bottom line
The cleanest framing is that federal nuclear support is mostly a future option, not a current balance-sheet asset, for this peer group.
Oklo has the most support in progress and therefore the most to gain if policy pathways mature, but it also has the most exposure if future credits, financing access, or commercial liability coverage fail to materialize.
Energy Fuels, NuScale, NANO Nuclear, and ASP Isotopes have less current support from this specific policy triad, which means they also have less direct exposure to a reversal of benefits they do not yet hold.
The report does not argue that policy does not matter. It argues that investors should distinguish between realized financing, existing legal coverage, and narrative optionality before assigning a cost-of-capital discount.
What readers get in the full PDF
Upgrade to access the complete policy-support analysis, including:
A detailed walkthrough of DOE Title 17 and Energy Dominance Financing, including the current pricing structure, recent closed transactions, and why pre-revenue developers have not yet received comparable support.
The full Price-Anderson liability map, including the difference between large-reactor coverage, sub-100 MW coverage, DOE contractor indemnity, materials licenses, and enrichment-plant exclusions.
A deeper analysis of Sections 45U, 48E, 6417, and 6418, including what direct pay, transferability, and stacked credit value could mean if future projects become eligible.
Individual deep dives on UUUU, OKLO, SMR, NNE, and ASPI, with balance-sheet context, current legal status, and company-specific reversal risks.
The full policy-support framework, catalyst matrix, and the exact events that could expand or reduce each company’s access to federal financing, liability protection, or tax-credit support.
FULL 20-PAGE PDF BELOW:
